Ocular toxoplasmosis II: Clinical features, pathology and management

Nicholas J. Butler, João M. Furtado, Kevin Winthrop, Justine R. Smith

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The term, ocular toxoplasmosis, refers to eye disease related to infection with the parasite, Toxoplasma gondii. Recurrent posterior uveitis is the typical form of this disease, characterized by unilateral, necrotizing retinitis with secondary choroiditis, occurring adjacent to a pigmented retinochoroidal scar and associated with retinal vasculitis and vitritis. Multiple atypical presentations are also described, and severe inflammation is observed in immunocompromised patients. Histopathological correlations demonstrate focal coagulative retinal necrosis, and early in the course of the disease, this inflammation is based in the inner retina. For typical ocular toxoplasmosis, a diagnosis is easily made on clinical examination. In atypical cases, ocular fluid testing to detect parasite DNA by polymerase chain reaction or to determine intraocular production of specific antibody may be extremely helpful for establishing aetiology. Given the high seroprevalence of toxoplasmosis in most communities, serological testing for T.gondii antibodies is generally not useful. Despite a lack of published evidence for effectiveness of current therapies, most ophthalmologists elect to treat patients with ocular toxoplasmosis that reduces or threatens to impact vision. Classic therapy consists of oral pyrimethamine and sulfadiazine, plus systemic corticosteroid. Substantial toxicity of this drug combination has spurred interest in alternative antimicrobials, as well as local forms of drug delivery. At this time, however, no therapeutic approach is curative of ocular toxoplasmosis.

Original languageEnglish (US)
Pages (from-to)95-108
Number of pages14
JournalClinical and Experimental Ophthalmology
Volume41
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Ocular Toxoplasmosis
Clinical Pathology
Retinal Vasculitis
Choroiditis
Posterior Uveitis
Inflammation
Sulfadiazine
Retinitis
Pyrimethamine
Parasitic Diseases
Eye Diseases
Toxoplasmosis
Toxoplasma
Seroepidemiologic Studies
Immunocompromised Host
Drug Combinations
DNA-Directed DNA Polymerase
Antibody Formation
Cicatrix
Retina

Keywords

  • Clinical
  • Diagnosis
  • Ocular toxoplasmosis
  • Pathology
  • Treatment
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ocular toxoplasmosis II : Clinical features, pathology and management. / Butler, Nicholas J.; Furtado, João M.; Winthrop, Kevin; Smith, Justine R.

In: Clinical and Experimental Ophthalmology, Vol. 41, No. 1, 01.2013, p. 95-108.

Research output: Contribution to journalArticle

Butler, Nicholas J. ; Furtado, João M. ; Winthrop, Kevin ; Smith, Justine R. / Ocular toxoplasmosis II : Clinical features, pathology and management. In: Clinical and Experimental Ophthalmology. 2013 ; Vol. 41, No. 1. pp. 95-108.
@article{1aa633c9793c42a39144d01df46ce17b,
title = "Ocular toxoplasmosis II: Clinical features, pathology and management",
abstract = "The term, ocular toxoplasmosis, refers to eye disease related to infection with the parasite, Toxoplasma gondii. Recurrent posterior uveitis is the typical form of this disease, characterized by unilateral, necrotizing retinitis with secondary choroiditis, occurring adjacent to a pigmented retinochoroidal scar and associated with retinal vasculitis and vitritis. Multiple atypical presentations are also described, and severe inflammation is observed in immunocompromised patients. Histopathological correlations demonstrate focal coagulative retinal necrosis, and early in the course of the disease, this inflammation is based in the inner retina. For typical ocular toxoplasmosis, a diagnosis is easily made on clinical examination. In atypical cases, ocular fluid testing to detect parasite DNA by polymerase chain reaction or to determine intraocular production of specific antibody may be extremely helpful for establishing aetiology. Given the high seroprevalence of toxoplasmosis in most communities, serological testing for T.gondii antibodies is generally not useful. Despite a lack of published evidence for effectiveness of current therapies, most ophthalmologists elect to treat patients with ocular toxoplasmosis that reduces or threatens to impact vision. Classic therapy consists of oral pyrimethamine and sulfadiazine, plus systemic corticosteroid. Substantial toxicity of this drug combination has spurred interest in alternative antimicrobials, as well as local forms of drug delivery. At this time, however, no therapeutic approach is curative of ocular toxoplasmosis.",
keywords = "Clinical, Diagnosis, Ocular toxoplasmosis, Pathology, Treatment, Uveitis",
author = "Butler, {Nicholas J.} and Furtado, {Jo{\~a}o M.} and Kevin Winthrop and Smith, {Justine R.}",
year = "2013",
month = "1",
doi = "10.1111/j.1442-9071.2012.02838.x",
language = "English (US)",
volume = "41",
pages = "95--108",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ocular toxoplasmosis II

T2 - Clinical features, pathology and management

AU - Butler, Nicholas J.

AU - Furtado, João M.

AU - Winthrop, Kevin

AU - Smith, Justine R.

PY - 2013/1

Y1 - 2013/1

N2 - The term, ocular toxoplasmosis, refers to eye disease related to infection with the parasite, Toxoplasma gondii. Recurrent posterior uveitis is the typical form of this disease, characterized by unilateral, necrotizing retinitis with secondary choroiditis, occurring adjacent to a pigmented retinochoroidal scar and associated with retinal vasculitis and vitritis. Multiple atypical presentations are also described, and severe inflammation is observed in immunocompromised patients. Histopathological correlations demonstrate focal coagulative retinal necrosis, and early in the course of the disease, this inflammation is based in the inner retina. For typical ocular toxoplasmosis, a diagnosis is easily made on clinical examination. In atypical cases, ocular fluid testing to detect parasite DNA by polymerase chain reaction or to determine intraocular production of specific antibody may be extremely helpful for establishing aetiology. Given the high seroprevalence of toxoplasmosis in most communities, serological testing for T.gondii antibodies is generally not useful. Despite a lack of published evidence for effectiveness of current therapies, most ophthalmologists elect to treat patients with ocular toxoplasmosis that reduces or threatens to impact vision. Classic therapy consists of oral pyrimethamine and sulfadiazine, plus systemic corticosteroid. Substantial toxicity of this drug combination has spurred interest in alternative antimicrobials, as well as local forms of drug delivery. At this time, however, no therapeutic approach is curative of ocular toxoplasmosis.

AB - The term, ocular toxoplasmosis, refers to eye disease related to infection with the parasite, Toxoplasma gondii. Recurrent posterior uveitis is the typical form of this disease, characterized by unilateral, necrotizing retinitis with secondary choroiditis, occurring adjacent to a pigmented retinochoroidal scar and associated with retinal vasculitis and vitritis. Multiple atypical presentations are also described, and severe inflammation is observed in immunocompromised patients. Histopathological correlations demonstrate focal coagulative retinal necrosis, and early in the course of the disease, this inflammation is based in the inner retina. For typical ocular toxoplasmosis, a diagnosis is easily made on clinical examination. In atypical cases, ocular fluid testing to detect parasite DNA by polymerase chain reaction or to determine intraocular production of specific antibody may be extremely helpful for establishing aetiology. Given the high seroprevalence of toxoplasmosis in most communities, serological testing for T.gondii antibodies is generally not useful. Despite a lack of published evidence for effectiveness of current therapies, most ophthalmologists elect to treat patients with ocular toxoplasmosis that reduces or threatens to impact vision. Classic therapy consists of oral pyrimethamine and sulfadiazine, plus systemic corticosteroid. Substantial toxicity of this drug combination has spurred interest in alternative antimicrobials, as well as local forms of drug delivery. At this time, however, no therapeutic approach is curative of ocular toxoplasmosis.

KW - Clinical

KW - Diagnosis

KW - Ocular toxoplasmosis

KW - Pathology

KW - Treatment

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84873852946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873852946&partnerID=8YFLogxK

U2 - 10.1111/j.1442-9071.2012.02838.x

DO - 10.1111/j.1442-9071.2012.02838.x

M3 - Article

C2 - 22712598

AN - SCOPUS:84873852946

VL - 41

SP - 95

EP - 108

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 1

ER -